#ZBIO hashtag - Bluesky

Pomerantz Law Firm Launches Investigation Into Zenas BioPharma, Inc. Investor Claims Zenas BioPharma faces scrutiny as Pomerantz Law Firm investigates potential securities fraud claims, following troubling trial results.

1 month ago

Pomerantz Law Firm Launches Investigation Into Zenas BioPharma, Inc. Investor Claims #United_States #New_York #Pomerantz_Law_Firm #Zenas_BioPharma #ZBIO

0 0 0 0

Pomerantz Law Firm Investigates Potential Securities Fraud Against Zenas BioPharma, Inc. (ZBIO) Pomerantz Law Firm is actively looking into claims about Zenas BioPharma, Inc. regarding possible securities fraud involving their recent Phase 3 trial results.

2 months ago

Pomerantz Law Firm Investigates Potential Securities Fraud Against Zenas BioPharma, Inc. (ZBIO) #USA #New_York #Pomerantz_Law #Zenas_BioPharma #ZBIO

0 0 0 0

Pomerantz Law Firm Probes Potential Securities Fraud at Zenas BioPharma Following Disappointing Results Pomerantz LLP is investigating possible securities fraud claims against Zenas BioPharma Inc. due to disappointing trial results. Affected investors should reach out for guidance.

3 months ago

Pomerantz Law Firm Probes Potential Securities Fraud at Zenas BioPharma Following Disappointing Results #USA #New_York #Pomerantz_LLP #Zenas_BioPharma #ZBIO

0 0 0 0

PRISM MarketView

@prismmarketview.bsky.social

3 months ago

PRISM M☀️rning M☀️vers

Premarket Gainers:
Mobix Labs, Inc. ( #MOBX) up 53%
VerifyMe, Inc. ( #VRME) up 45%
GH Research PLC ( #GHRS) up 44%
Momentus Inc. ( #MNTS) up 38%

Premarket Decliners:
Trio-Tech International ( #TRT) down -48%
Zenas BioPharma, Inc. ( #ZBIO) down- 46%

0 0 0 0

Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) Zenas BioPharma (Nasdaq: ZBIO) announced positive Phase 3 INDIGO results for obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD). Obexelimab met the primary endpoint with a 56% reduction in risk of IgG4-RD flare versus placebo (Hazard Ratio 0.44, p=0.0005) over 52 weeks and achieved statistically significant results on all four key secondary endpoints. The drug was well tolerated with no new safety signals, similar injection site reaction rates, and lower infection rates versus placebo. Zenas plans to submit a BLA to FDA in Q2 2026 and an MAA to EMA in H2 2026. Full INDIGO data will be presented at a future medical meeting and a conference call was scheduled for January 5, 2026.

3 months ago

#ZBIO Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)

www.stocktitan.net/news/ZBIO/zenas-bio-phar...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

4 months ago

Leading Indicators, Thursday November 13, 2025 – Crystal Equity Research

Small-cap stocks with improving money flow, Thu Nov 13th - #CREX #KROS #ZBIO #SHIP #ROOT #PLUS #NAUT #MESA #GECC #CCII #AMAL #NCDL #MFA #HGTY #FPH #EB - More: crystalequityresearch.com/leading-indi... - #smallcap

0 0 0 0

Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease (IgG4-RD) expected around year-end 2025 - - Reported highly positive 12-week primary endpoint results from Phase 2 MoonStone trial of obexelimab in Relapsing MS (RMS) - - Secured development and commercialization

4 months ago

#ZBIO Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/ZBIO/zenas-bio-phar...

0 0 0 0

Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage

5 months ago

#ZBIO Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis

www.stocktitan.net/news/ZBIO/zenas-bio-phar...

0 0 0 0

$300M Funding Deal: Zenas BioPharma's Novel Autoimmune Drug Obexelimab Backed by Royalty Pharma Biotech funding agreement includes $75M upfront plus $225M in milestone payments. Phase 3 IgG4-RD trial results expected year-end, with potential FDA approval and launch in 2027.

7 months ago

#ZBIO Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million

www.stocktitan.net/news/ZBIO/zenas-bio-phar...

0 0 0 0

Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates Zenas BioPharma (NASDAQ:ZBIO) has reported its Q2 2025 financial results and provided updates on its clinical programs. The company ended Q2 with $274.9 million in cash and investments, providing runway into Q4 2026.Key clinical developments include: expected topline results from the Phase 3 INDIGO trial in IgG4-Related Disease by year-end 2025, completed enrollment in the Phase 2 MoonStone trial for Relapsing Multiple Sclerosis with results expected in early Q4 2025, and ongoing enrollment in the Phase 2 SunStone trial for Systemic Lupus Erythematosus with completion expected by year-end 2025.Financial results show R&D expenses increased to $43.0 million from $33.8 million year-over-year, while G&A expenses rose to $12.1 million from $5.9 million. Net loss widened to $52.2 million compared to $38.0 million in Q2 2024.

7 months ago

#ZBIO Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

www.stocktitan.net/news/ZBIO/zenas-bio-phar...

0 0 0 0

Last Chance for ZBIO Investors to Lead Securities Fraud Class Action Against Zenas BioPharma Zenas BioPharma Inc. faces a class action lawsuit by Schall Law Firm for alleged securities fraud related to misleading IPO announcements. Act quickly.

9 months ago

Last Chance for ZBIO Investors to Lead Securities Fraud Class Action Against Zenas BioPharma #United_States #Los_Angeles #Securities_Fraud #Zenas_BioPharma #ZBIO

0 0 0 0

ZBIO Shareholders Have Opportunity to Join Zenas Biopharma Class Action Lawsuit Attention ZBIO investors: Join the class action against Zenas Biopharma for alleged securities violations. Contact DJS Law Group for details.

9 months ago

ZBIO Shareholders Have Opportunity to Join Zenas Biopharma Class Action Lawsuit #USA #DJS_Law_Group #Eastchester #Zenas_BioPharma #ZBIO

0 0 0 0

Zenas BioPharma Investors Alerted About Class Action Lawsuit Opportunity Investors in Zenas BioPharma facing losses exceeding $100K are urged to join a securities class action lawsuit. The lead plaintiff deadline is June 16, 2025.

9 months ago

Zenas BioPharma Investors Alerted About Class Action Lawsuit Opportunity #United_States #New_York #Zenas_BioPharma #ZBIO #The_Rosen_Law_Firm

0 0 0 0

ZBIO Shareholders Pursue Class Action Against Zenas Biopharma for Securities Violations Zenas Biopharma faces a class action lawsuit from ZBIO shareholders regarding securities law violations. Discover how to join the action.

9 months ago

ZBIO Shareholders Pursue Class Action Against Zenas Biopharma for Securities Violations #USA #DJS_Law_Group #Eastchester #Zenas_BioPharma #ZBIO

0 0 0 0

Zenas BioPharma Shareholders Encouraged to Join Class Action for Recovery The Gross Law Firm calls Zenas BioPharma shareholders to join a class action lawsuit by June 16, 2025, for potential recovery of losses.

10 months ago

Zenas BioPharma Shareholders Encouraged to Join Class Action for Recovery #United_States #New_York #Gross_Law_Firm #Zenas_BioPharma #ZBIO

0 0 0 0

ZBIO Shareholders Take Charge in Zenas Biopharma Class Action Lawsuit Investors encouraged to join the class action lawsuit against Zenas Biopharma, Inc. for misleading statements during its IPO.

10 months ago

ZBIO Shareholders Take Charge in Zenas Biopharma Class Action Lawsuit #USA #DJS_Law_Group #Eastchester #Zenas_BioPharma #ZBIO

0 0 0 0

Investors of Zenas BioPharma Face Class Action Lawsuit with Upcoming Deadline Zenas BioPharma investors are alerted to a class action lawsuit filed by Levi & Korsinsky. A deadline for lead plaintiff appointments is approaching.

10 months ago

Investors of Zenas BioPharma Face Class Action Lawsuit with Upcoming Deadline #United_States #New_York #Levi_&_Korsinsky #Zenas_BioPharma #ZBIO

0 0 0 0

ZBIO Shareholders Entitled to Lead Legal Action Against Zenas Biopharma, Inc. DJS Law Group alerts ZBIO investors about their rights to lead a securities lawsuit against Zenas Biopharma, Inc. for federal securities law violations.

10 months ago

ZBIO Shareholders Entitled to Lead Legal Action Against Zenas Biopharma, Inc. #USA #DJS_Law_Group #Eastchester #Zenas_BioPharma #ZBIO

0 0 0 0

ZBIO Investors Encouraged to Join Zenas BioPharma Securities Fraud Class Action Zenas BioPharma faces a class action lawsuit for securities fraud after misleading investors during its IPO. Join now to recover losses.

10 months ago

ZBIO Investors Encouraged to Join Zenas BioPharma Securities Fraud Class Action #USA #Los_Angeles #Securities_Fraud #Zenas_BioPharma #ZBIO

0 0 0 0

Robbins LLP Encourages ZBIO Stockholders to Step Forward for Class Action Initiative Robbins LLP invites Zenas BioPharma stockholders to join a class action lawsuit. Investors may recover losses experienced after the company's IPO.

10 months ago

Robbins LLP Encourages ZBIO Stockholders to Step Forward for Class Action Initiative #United_States #San_Diego #Robbins_LLP #Zenas_BioPharma #ZBIO

0 0 0 0

Levi & Korsinsky Alerts Zenas BioPharma Shareholders About Upcoming Class Action Lawsuit Deadline in 2025 Investors in Zenas BioPharma, Inc. should note the upcoming class action lawsuit deadline on June 16, 2025, as Levi & Korsinsky informs affected shareholders.

10 months ago

Levi & Korsinsky Alerts Zenas BioPharma Shareholders About Upcoming Class Action Lawsuit Deadline in 2025 #United_States #New_York #Class_Action #Zenas_BioPharma #ZBIO

0 0 0 0

Investors of Zenas BioPharma Encouraged to Lead Class Action Lawsuit Zenas BioPharma faces a class action lawsuit over alleged securities fraud following its IPO. Investors are urged to join for possible recovery.

10 months ago

Investors of Zenas BioPharma Encouraged to Lead Class Action Lawsuit #United_States #Los_Angeles #Schall_Law_Firm #Zenas_BioPharma #ZBIO

0 0 0 0